Viability of Dugesia dorotocephala Planaria with the Senolytic Drug ARV-825

Planaria ( <i>Dugesia dorotocephala</i> ) are being utilized as a model system to test the effectiveness of ARV-825. ARV-825 belongs to the drug class proteolysis targeting chimeras (PROTACs), which targets and degrades the protein Bromodomain-containing protein 4 (BRD4) via the proteasome. To examine the impact of ARV-825 on the planaria, planaria viability was tested at different ARV-825 concentrations. This demonstrated a concentration-dependent reduction in viability, 91.7% survival with 1µM ARV-825 reduced to 25% survival in 10 µM ARV-825. This suggests ARV-825 has an effect on <i>Dugesia dorotocephala</i> , and indicates that this may be a suitable model organism for studying ARV-825.